ArticleCancer reports (Hoboken, N.J.)2026
Profillin-1 and Transgelin-2: Actin Binding Proteins Expression in Early and Advanced Stages of Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) is known for its more aggressive clinical behavior, poor prognosis, and distinctive patterns of metastasis. Neoadjuvant chemotherapy (NAC) can influence both tumor cells and the tumor microenvironment. Emerging evidence highlights the critical role of actin cytoskeletal dynamics in cancer progression.
aimsThis study aimed to explore the expression of two actin binding proteins, profilin-1 (PFN-1) and transgelin-2 (TAGLN-2), before and after NAC. Their prognostic significance, particularly in response to NAC in TNBC, has not been fully elucidated. Their expression patterns may provide valuable insight into their prognostic value and treatment response. METHODS AND
resultsThis quasi-experimental study included 54 females (aged 24-45 years) diagnosed with TNBC pre- and post-treated NAC and age matched healthy donors (n = 30). The strategy encompasses sequential high-resolution Reverse-Phase Liquid Chromatography Mass Spectrometry (RPLC-MS/MS) for identification of peptides followed by ELISA and RT-qPCR. An in silico analysis, STRING and KEGG analysis were also employed. The PFN-1 protein and gene expression in early stages (I & II) of pre-NAC were significantly (p = 0.0001) higher. However, in the post-NAC patients with advanced stages, expression was reduced. The TGLN-2 protein concentration was significantly higher (p = 0.0001) in the pre-NAC group at advanced stages compared with post-NAC patients. Gene expression of TGLN-2 is highly overexpressed in both groups at advanced stages. Moreover, tumor suppressor gene PTEN was downregulated at early stages of pre and post-NAC groups and upregulated at advanced stages of post-NAC. STRING and KEGG analysis showed that PFN-1 and TGLN-2 both displayed association with regulation of actin cytoskeleton.
conclusionAberrantly expression of actin binding proteins, PFN-1 and TAGLN-2 and tumor suppressor gene PTEN in pre and post-NAC patients in different tumor stages compared with healthy individuals can provide valuable prognostic information and may have potential as a therapeutic target. The observed interactions of PFN-1 with VASP and potential crosstalk with TAGLN-2 point toward their collective role in actin cytoskeleton regulation and tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.